Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes
- 23 March 2009
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 31 (7) , 944-948
Abstract
Background. Our aim was to determine whether percutaneous endoscopic gastrostomy (PEG) dependence was significantly different between 2 prospective trials with different radiation fractionation schemes. Methods. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionation (A-3 protocol) or accelerated fractionation (A-4 protocol) with chemotherapy. Amifostine was administered 15 to 30 minutes preradiation, at a dose of 500 mg/day in both protocols. It was given as an infusion over 5 to 7 minutes (A-3 protocol) or subcutaneously (A-4 protocol). Data regarding PEG placement and removal were collected prospectively. Results. Thirty-five evaluable A-3 protocol patients, 14 evaluable A-4 protocol patients, and 6 patients treated per A-4 protocol guidelines, but without amifostine as they refused the medication, were included in the analysis. Pretreatment characteristics, such as sex, age, race, T classification, N classification, American Joint Committee on Cancer (AJCC) stage, were compared between the 2 groups of patients. The only significant difference between the 2 groups was AJCC stage. Thirty-five A-3 patients and 20 A-4 patients had overall survivals of 88% versus 80%, 82% versus 75%, and 66% versus 67.5% at 1, 2, and 3 years, respectively (p = .958). With regard to PEG dependence, no significant differences were seen between the 2 groups at 6, 12, or 18 months. Conclusion. PEG dependence was not significantly different between the 2 study groups. Type of altered fractionation scheme may not influence PEG dependence in patients treated with similar protocols. Future randomized studies are needed to confirm these findings. © 2009 Wiley Periodicals, Inc. Head Neck, 2009Keywords
This publication has 9 references indexed in Scilit:
- Intensity‐modulated radiation therapy use in the U.S., 2004Cancer, 2005
- Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a phase II trial of the RTOG (99-14)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head-and-neck cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Current management of the nutritional needs of the head and neck cancer patientCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2000
- Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx CarcinomaJNCI: Journal of the National Cancer Institute, 1999
- Eating and Weight Changes Following Chemoradiation Therapy for Advanced Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 1998
- Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complicationsHead & Neck, 1997
- Percutaneous Endoscopic Gastrostomy: A Useful Tool for the Otolaryngologist--Head and Neck SurgeonJAMA Otolaryngology–Head & Neck Surgery, 1995